Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III–IV melanoma in phase III trial E1609
Titel:
Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III–IV melanoma in phase III trial E1609
Auteur:
McLouth, Laurie E. Zheng, Yue Smith, Stephanie Hodi, F. Stephen Rao, Uma N. Cohen, Gary I. Amatruda, Thomas T. Dakhil, Shaker R. Curti, Brendan D. Nakhoul, Ibrahim Chandana, Sreenivasa R. Bane, Charles L. Marinier, David E. Lee, Sandra J. Sondak, Vernon K. Kirkwood, John M. Tarhini, Ahmad A. Wagner, Lynne I.